Li L, et al. - Authors analyzed the clinical data of 55 preterm newborns and 180 term infants with infantile hemangioma (IH) treated with oral propranolol for 6 months retrospectively to assess the correlation between treatment of IH with propranolol (in preterm babies vs term infants) and higher incidences of long-term adverse effects and growth impairment. No significant differences were obtained in terms of general features and adverse effect incidence among preterm and term patients. At ages 1, 2, and 3 years, no significant variations were reported in height, weight, and head circumference of the preterm infants when compared to the normal references. But, only 1-year-old female weight and head circumference were found significantly higher as compared to the normal references in the term patients. They did not report any increase in the risks for adverse effects or growth impairment up to age 3 years with the treatment of IH with propranolol for 6 months in preterm vs term patients.